Write-offs Archives - PharmaLive

Bristol Myers Takes $470 Million Write-off and Scraps Orva-Cel CAR-T Program

B-cell maturation antigen (BCMA), Biologics License Application (BLA), Bristol Myers Squibb, Business, CAR-T Therapy, Clinical Trials, PDUFA, R&D, Relapsed Or Refractory (R/R) Large B-Cell Lymphoma (LBCL), Therapeutics, Write-offs

Bristol Myers Squibb reported that the company was abandoning the BCMA CAR-T therapy orva-cel and taking a $470 million write-off.

February 11, 2021/by Andrew Humphreys

Novartis

Novartis Writes Off Advair Copycat Program, Posts Strong Q4 2019 Results

Asthma, Blockbusters, Financials, Generics, Inhalers, Quarterly results, Write-offs

Swiss pharma giant Novartis is writing off the company’s program to develop a generic copy of GlaxoSmithKline’s blockbuster inhaler Advair.

January 30, 2020/by BioSpace